Since more than 50 years glucocorticoids represent the milestone in the treatment of inflammatory diseases, including rheumatoid arthritis (RA). However, many patients with RA present a circadian rhythm in symptoms severity, with a significant worsening in the morning, that correlates with cyclic changes in circulating hormones and cytokines. Classical steroids therapy given in the morning fails to intercept this pathophysiological phenomenon. In the last years, a novel formulation of prednisone has been developed in order to better fit these variations, improve efficacy and minimize adverse events (chronotherapy). This modified-release (MR) prednisone is administered in the evening at 10.00 p.m. and absorbed after about 4 hours. In the present article we reviewed the evidence supporting a role for MR prednisone in the treatment of RA patients.
Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
Grembiale R
2017-01-01
Abstract
Since more than 50 years glucocorticoids represent the milestone in the treatment of inflammatory diseases, including rheumatoid arthritis (RA). However, many patients with RA present a circadian rhythm in symptoms severity, with a significant worsening in the morning, that correlates with cyclic changes in circulating hormones and cytokines. Classical steroids therapy given in the morning fails to intercept this pathophysiological phenomenon. In the last years, a novel formulation of prednisone has been developed in order to better fit these variations, improve efficacy and minimize adverse events (chronotherapy). This modified-release (MR) prednisone is administered in the evening at 10.00 p.m. and absorbed after about 4 hours. In the present article we reviewed the evidence supporting a role for MR prednisone in the treatment of RA patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
